| Third Harmonic Bio Announces Plan of Liquidation and Dissolution |
Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 |
globenewswire.com |
2025-04-14 10:45:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results |
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) |
globenewswire.com |
2025-03-27 10:10:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-03-04 12:35:30 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? |
Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-14 15:06:14 |
Czytaj oryginał (ang.) |
| Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) |
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-02-14 12:36:13 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape |
On Tuesday, Third Harmonic Bio, Inc. THRD revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. |
benzinga.com |
2025-02-12 18:41:39 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update |
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced results from its Phase 1 single and multiple ascending dose (SAD/MAD) clinical trial of THB335 in healthy volunteers. |
globenewswire.com |
2025-02-11 09:00:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference |
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m. |
globenewswire.com |
2024-11-25 18:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Third Harmonic Bio, Inc. (THRD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-11 13:00:35 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio to Participate in Upcoming Investor Conferences in November |
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences: |
globenewswire.com |
2024-11-07 18:00:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces Third Quarter 2024 Financial Results |
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. “As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress in preparing to move efficiently into a Phase 2 clinical trial in chronic spontaneous urticaria,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio. |
globenewswire.com |
2024-11-07 10:10:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio to Participate in Upcoming Investor Conferences in September |
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences: |
globenewswire.com |
2024-09-10 20:00:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio to Participate in Upcoming Investor Conferences |
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences: |
globenewswire.com |
2024-08-26 20:00:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update |
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the second quarter June 30, 2024, along with business updates. “We are making excellent progress in our Phase 1 SAD/MAD clinical trial of THB335 and now expect to report clinical results during the first quarter of 2025,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio. |
globenewswire.com |
2024-08-08 12:05:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference |
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET. |
globenewswire.com |
2024-05-28 20:05:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update |
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H'25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D. |
globenewswire.com |
2024-05-15 12:05:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors |
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. |
globenewswire.com |
2024-03-28 10:30:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results |
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. “Our team's execution continues to be outstanding, with the filing of our U.S. IND for THB335 ahead of our internal timelines for submission,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. |
globenewswire.com |
2024-03-26 10:05:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference |
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET. |
globenewswire.com |
2024-02-26 18:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD) |
NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The investigation seeks to determine whether Third Harmonic Bio's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2024-02-22 13:08:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update |
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy |
globenewswire.com |
2024-01-04 10:00:00 |
Czytaj oryginał (ang.) |
| Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice |
Does Third Harmonic Bio, Inc. (THRD) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2023-12-29 15:32:16 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD) |
NEW YORK , Nov. 9, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The investigation seeks to determine whether Third Harmonic Bio's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2023-11-09 11:35:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces Third Quarter 2023 Financial Results |
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H'24 |
globenewswire.com |
2023-11-09 10:30:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces Leadership Changes |
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023. In his new role, Dr. Ray will continue support the company's Investigational New Drug (IND) application for THB335, which is expected to be filed during the first half of 2024. Additionally, the company announced that Robert Ho, Chief Financial Officer, will depart the organization on November 10, 2023. The company has initiated executive searches for their successors. |
globenewswire.com |
2023-10-31 10:30:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference |
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET. |
globenewswire.com |
2023-08-31 12:30:00 |
Czytaj oryginał (ang.) |
| Third Harmonic Bio Announces Second Quarter 2023 Financial Results |
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution, and physicochemical profile |
globenewswire.com |
2023-08-10 12:10:00 |
Czytaj oryginał (ang.) |